Dorner, MA
Andrew Dorner, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20090220983 | CELL-BASED METHODS FOR DETECTING AND/OR MEASURING BMP-12-RELATED PROTEIN ACTIVITY - The invention provides cell-based methods to detect and/or measure the BMP-12-related protein activity of a sample containing a BMP-12-related protein. The methods involve contacting a suitable cell with the sample, and measuring the expression level of at least one BMP-12-related-activity-marker. A dose-dependent increase(s) in the level(s) of the BMP-12-related-activity-markers is indicative of the BMP-12-related protein activity in the sample. The levels of the BMP-12-related-activity-markers of the invention exhibit a dose-responsive increase in response to known BMP-12-related proteins BMP-12, BMP-13, and MP-52, but not to the osteogenic protein, BMP-2. | 09-03-2009 |
Andrew J. Dorner, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20100124536 | Hemophilia Treatment by Inhalation of Coagulation Factors - Hemophilia treatment by the inhalation of coagulation factors. Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 μm or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and deeply inhaled into the lung, and followed by a maximal exhale. | 05-20-2010 |
Andrew J. Dorner, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20080206261 | METHODS FOR SCREENING, TREATING AND DIAGNOSING INFLAMMATORY BOWEL DISEASE AND COMPOSITIONS THEREOF - Methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of IBD. In particular, the present invention is directed to the identification of novel targets that are IBD differential markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit IBD. Methods for determining the long-term prognosis in a subject are also provided. | 08-28-2008 |
20080280774 | Methods and Systems for Diagnosis, Prognosis and Selection of Treatment of Leukemia - The present invention provides methods, systems and equipment for the prognosis, diagnosis and selection of treatment of AML or other types of leukemia. Genes prognostic of clinical outcome of leukemia patients can be identified according to the present invention. Leukemia disease genes can also be identified according to the present invention. These genes are differentially expressed in PBMCs of AML patients relative to disease-free humans. These genes can be used for the diagnosis or monitoring the development, progression or treatment of AML. | 11-13-2008 |
Andrew Joseph Dorner, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20080226645 | Methods and compositions for assessment and treatment of asthma - The present invention provides methods and compositions for the assessment and treatment of asthma and other inflammatory diseases, particularly those mediated by interleukin-13 (IL-13). The present invention also provides arrays comprising markers for asthma as well as IL-13 responsiveness. The markers of the present invention can be used in methods to diagnose a patient as having asthma or an IL-13-mediated condition, to evaluate the effectiveness of potential therapeutic agents, to identify or evaluate agents capable of modulating marker expression levels, and to select a treatment for a patient suffering from asthma or an IL-13-mediated condition. | 09-18-2008 |
20090061423 | PHARMACOGENOMIC MARKERS FOR PROGNOSIS OF SOLID TUMORS - The present invention provides methods, systems and equipment for prognosis or evaluation of treatment of solid tumors. Gene markers that are prognostic of solid tumors can be identified according to the present invention. Each gene marker has altered expression patterns in PBMCs of solid tumor patients following initiation of an anti-cancer treatment, and the magnitudes of these alterations are correlated with clinical outcomes of these patients. In one embodiment, a Cox proportional hazards model is used to determine the correlations between clinical outcomes of RCC patients and gene expression changes in PBMCs of these patients during the course of a CCI-779 treatment. Non-limiting examples of genes identified by the Cox model are depicted in Tables 4A3 4B, 5 A and 5B. These genes can be used as surrogate markers for prognosis of RCC. They can also be used as pharmacogenomic indicators for the efficacy of CCI-779 or other anti-cancer drugs. | 03-05-2009 |
20090155784 | ASSESSMENT OF ASTHMA AND ALLERGEN-DEPENDENT GENE EXPRESSION - The present invention provides methods for the assessment, diagnosis, or prognosis of asthma including methods for providing an assessment, diagnosis, or prognosis comprising the step of exposing a sample derived from a patient to an allergen in vitro. The present invention also provides methods for selecting, as well as evaluating the effectiveness of, asthma treatments. The markers of the present invention can be used in methods to identify or evaluate agents capable of modulating marker expression levels in subjects with asthma | 06-18-2009 |
20090325176 | Gene Expression Profiles Associated with Asthma Exacerbation Attacks - The present invention provides methods for the assessment, diagnosis, or prognosis of asthma exacerbation, by assessing the level of expression of asthma exacerbation gene products in a sample derived from a patient. The markers of the present invention can be used in methods to identify or evaluate agents capable of modulating marker expression levels in subjects with asthma. | 12-31-2009 |